Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Gustatory Dysfunction in Multiple Sclerosis
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Mitoxantrone-induced suicidal erythrocyte death.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Fingolimod is a potential novel therapy for multiple sclerosis.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Vitamin D intake and incidence of multiple sclerosis.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Pharmacokinetic properties and metabolism of idebenone.

Pages